Company intelligence / Profile preview

NeXtGen Biologics

Alachua, Florida, United Statesrepublic.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeXtGen Biologics has developed NeoMatriX®, the first FDA-cleared extracellular matrix wound healing product derived from axolotl tissue. Clinical studies demonstrated no immunological response in humans and no delay in wound healing in animal models. The product is available as sterile sheets for use on acute and chronic wounds, with ongoing development of additional formulations for broader surgical and regenerative uses.

Therapeutic areas: OtherDermatologyCardiovascularOphthalmologyNeurology
Modalities: Extracellular matrix (ECM) biomaterialBiologic (derived from axolotl tissue)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

NEOMATRIX

Commercial

Indications: Surgical wounds, Diabetic ulcers, Burns, Chronic wounds, Acute wounds

Beyond the preview

Go deeper on NeXtGen Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeXtGen Biologics.

Explore the full profile